Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decrease of 14.2% from the January 15th total of 1,410,000 shares. Approximately 2.7% of the company’s stock are sold short. Based on an average trading volume of 179,200 shares, the days-to-cover ratio is currently 6.8 days.

Aura Biosciences Price Performance

Shares of Aura Biosciences stock opened at $7.95 on Monday. The business has a fifty day simple moving average of $8.08 and a two-hundred day simple moving average of $8.78. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The company has a market capitalization of $397.10 million, a price-to-earnings ratio of -4.60 and a beta of 0.29.

Analyst Ratings Changes

AURA has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and a consensus price target of $23.00.

Insiders Place Their Bets

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AURA. SG Americas Securities LLC bought a new position in Aura Biosciences during the 3rd quarter worth $169,000. Charles Schwab Investment Management Inc. increased its position in shares of Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares during the period. State Street Corp increased its position in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares during the period. Wellington Management Group LLP bought a new position in shares of Aura Biosciences in the third quarter worth $1,037,000. Finally, Barclays PLC increased its position in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the period. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.